Baudax Bio, Inc., a pharmaceutical company specializing in hospital and acute-care products, has recently introduced their latest product, ANJESO (meloxicam), for the management of moderate to severe pain. With the option to take it alone or paired with other non-NSAID analgesics, this injection offers a versatile solution for medical professionals. Additionally, the company has several ongoing projects in developmental phases, including BX1000, a neuromuscular blocking agent in phase II clinical trial; BX2000, an ultra-short acting NMB in phase I clinical trial with a proprietary blockade reversal agent; and BX3000, a NMB reversal agent currently in preclinical studies. Founded in 2019 and based in Malvern, Pennsylvania, Baudax Bio is quickly making strides in the healthcare industry.